SCHEMBL20459976

SCHEMBL20459976

COc1cncc(-c2ccc(C#N)c(F)c2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 20/20 1.00
CYP11B1 P15538 18/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20459955 0.82 CYP11B2 (1.00) CYP11B2CYP11B1
SCHEMBL20459995 0.81 CYP11B2 (1.00) CYP11B2CYP11B1
SCHEMBL20460012 0.80 CYP11B2 (1.00) CYP11B2CYP11B1
SCHEMBL20460051 0.79 CYP11B2 (1.00) CYP11B2CYP11B1
SCHEMBL21373703 0.79 CYP11B2 (0.67) CYP11B2CYP11B1
SCHEMBL20460032 0.79 CYP11B2 (1.00) CYP11B2CYP11B1
SCHEMBL20460009 0.78 CYP11B2 (1.00) CYP11B2CYP11B1
SCHEMBL16797374 0.77 CYP11B2 (0.63) CYP11B2CYP11B1
SCHEMBL20460011 0.77 CYP11B2 (1.00) CYP11B2CYP11B1
SCHEMBL20460019 0.77 CYP11B2 (0.64) CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018141541-A1 COMPOUND FOR IN VIVO DIAGNOSIS OF A DYSFUNCTION OF ADRENAL GLANDS JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) 2018-08-09 WO disclosed
EP-3357910-A1 COMPOUND FOR IN VIVO DIAGNOSIS OF A DYSFUNCTION OF ADRENAL GLANDS Julius-Maximilians-Universität Würzburg (DE) 2018-08-08 EP disclosed
US-20160067353-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2016-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160067353-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP CYP11B2 4511/4885CYP11B1 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.